bioAffinity Technologies raised approximately $3.6 million through a private Placement involving the issuance of pre-funded warrants and warrants to purchase common stock. This funding will bolster the company’s working capital, aiding future operational needs.

Key Highlights

  • The net proceeds from the private placement are intended for Working Capital and general corporate purposes.
  • BioAffinity Technologies, Inc. has raised approximately $3.6 million through a private placement that includes the issuance of pre-funded warrants and common stock.
  • Alongside these pre-funded warrants, the company has also issued Series A and Series B warrants, each permitting the Acquisition of the same amount of shares.

BioAffinity Technologies, Inc. has raised approximately $3.6 million through a private placement that includes the issuance of pre-funded warrants and common stock. This move significantly enhances the company's Liquidity position, providing resources essential for future operational initiatives. The successful closing of this placement on August 14, 2026, also reflects the company’s ongoing engagement with institutional investors focused on financing growth avenues.

Private Placement Details

Alongside these pre-funded warrants, the company has also issued Series A and Series B warrants, each permitting the acquisition of the same amount of shares. The structure of the warrants reflects strategic terms aimed at aligning investor interests with the company's operational goals and growth trajectory.

Financial Agreement Insights

In this transaction, bioAffinity Technologies secured a contractual agreement with WallachBeth Capital LLC, which served as the exclusive placement agent. The company plans to issue warrants to WallachBeth equating to 3% of the total shares sold in the offering, resulting in approximately 253,861 shares to the placement agent. This compensation structure incentivizes the placement agent while facilitating the capital raise, ensuring alignment with bioAffinity’s broader financial strategy.

Strategic Timing and Company Outlook

The timing of the private placement signals bioAffinity Technologies’ proactive approach in securing funding amidst market conditions. The intent to utilize the net proceeds for working capital and general corporate purposes underscores the group's commitment to strengthening its operational foundation. This financial maneuver is expected to position the company for continued development, indicating management's focus on enhancing its capabilities and resources moving forward.

Future Catalysts to Monitor

Looking ahead, bioAffinity Technologies plans to file a registration statement with the SEC, which is due no later than 15 days following the registration rights agreement dated August 12, 2026. The registration will cover the resale of the shares underlying these warrants, a important step for ensuring liquidity for its investors. The company aims to have this registration declared effective promptly, within 45 days, or within 75 days if a full review by the SEC is required.

This timely filing will be essential for potential investors and reflects the company’s commitment to transparency and market engagement.